Disease · MONDO_0007972
Comparisons in its trials26
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 26
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): deaths from any cause | 0 of 86 | 0 of 88 | 174 | NCT02717442 | Trial comparisons |
| OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): serious adverse events | 2 of 86 | 0 of 88 | 174 | NCT02717442 | Trial comparisons |
| OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): Otoscopic Examination - Tympanic Membrane Perforation at Week 12 (Month 3) | 4 of 82 | 0 of 83 | 165 | NCT02612337 | Trial comparisons |
| OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): deaths from any cause | 0 of 82 | 0 of 83 | 165 | NCT02612337 | Trial comparisons |
| OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): serious adverse events | 2 of 82 | 2 of 83 | 165 | NCT02612337 | Trial comparisons |
| OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): Audiometry - Shift in Air-Bone Gap at 2000 Hz From Baseline to Week 12 (Month 3) | 4 of 74 | 1 of 78 | 152 | NCT02612337 | Trial comparisons |
| OTO-104 vs Placebo: Otoscopic Examination - Presence of Perforation in the Treated Ear at Week 12 (Month 3) Final Visit | 0 of 73 | 0 of 75 | 148 | NCT03664674 | Trial comparisons |
| OTO-104 vs Placebo: deaths from any cause | 0 of 73 | 0 of 75 | 148 | NCT03664674 | Trial comparisons |
| OTO-104 vs Placebo: serious adverse events | 2 of 73 | 2 of 75 | 148 | NCT03664674 | Trial comparisons |
| OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): Audiometry - Shift in Air-Bone Gap at 1000 Hz From Baseline to Week 12 (Month 3) | 3 of 70 | 3 of 68 | 138 | NCT02612337 | Trial comparisons |
| OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): Audiometry - Shift in Air-Bone Gap at 500 Hz From Baseline to Week 12 (Month 3) | 2 of 62 | 7 of 70 | 132 | NCT02612337 | Trial comparisons |
| OTO-104 vs Placebo: Audiometry - Shift in Air-Bone Gap at 2000 Hz From Baseline to Week 12 (Month 3) | 4 of 62 | 4 of 64 | 126 | NCT03664674 | Trial comparisons |
| OTO-104 vs Placebo: Audiometry - Shift in Air-Bone Gap at 1000 Hz From Baseline to Week 12 (Month 3) | 5 of 55 | 7 of 58 | 113 | NCT03664674 | Trial comparisons |
| OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): Otoscopic Examination - Tympanic Membrane Perforation at Week 12 (Month 3) | 1 of 53 | 0 of 59 | 112 | NCT02717442 | Trial comparisons |
| OTO-104 vs Placebo: Audiometry - Shift in Air-Bone Gap at 4000 Hz From Baseline to Week 12 (Month 3) | 2 of 50 | 9 of 53 | 103 | NCT03664674 | Trial comparisons |
| OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): Audiometry - Shift in Air-Bone Gap at 500 Hz From Baseline to Week 12 (Month 3) | 8 of 48 | 7 of 52 | 100 | NCT02717442 | Trial comparisons |
| OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): Audiometry - Shift in Air-Bone Gap at 2000 Hz From Baseline to Week 12 (Month 3) | 0 of 42 | 4 of 51 | 93 | NCT02717442 | Trial comparisons |
| OTO-104 (Safety Analysis Set) vs Placebo (Safety Analysis Set): Audiometry - Shift in Air-Bone Gap at 1000 Hz From Baseline to Week 12 (Month 3) | 11 of 39 | 3 of 45 | 84 | NCT02717442 | Trial comparisons |
| Venlafaxine Arm vs Placebo: deaths from any cause | 0 of 40 | 0 of 40 | 80 | NCT04218123 | Trial comparisons |
| Venlafaxine Arm vs Placebo: serious adverse events | 0 of 40 | 0 of 40 | 80 | NCT04218123 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007972/comparisons